title: Fatty acid based hyperbranched polymeric nanoparticles for hydrophobic drug delivery.
abstract: BACKGROUND
  In recent years nano-sized dendrimer/hyperbranched polymers gained importance in drug delivery applications.
  
  
  OBJECTIVE
  In this study, a novel fatty acid-based hyperbranched resin (HBR) was synthesized and used for tamoxifen (TAM) and idarubicin (IDA) delivery.
  
  
  METHODS
  The core of the HBR was dipentaerythritol, and the branching was provided by dimethylolpropionic acid. The molecule was terminated by ricinoleic acid. Chemical and structural characterization of the resin was carried out and then drug-loading experiments were performed.
  
  
  CONCLUSIONS
  The loading efficiencies were found to be 73.3% for TAM and 74% for IDA. The Fourier transform infrared spectroscopy analysis showed that TAM physically bounded onto the resin whereas IDA interacted chemically. Controlled release in phosphate buffer was improved by Pseudomonas sp. lipase and sodium dodecyl sulfate. The release rates decreased with the increase of loading concentrations. The cytotoxicity analyses were carried out on MCF-7 breast cancer cells for both drug-free and drug-loaded HBR. Drug-free particles did not have significant toxicity. Drug-loaded nanoparticles caused higher levels of cell death than pure drugs.
authors.affiliation: Department of Biology, Middle East Technical University, Ankara, Turkey.
authors.forename: Esra
authors.initials: E
authors.lastname: Güç
authors.forename: Güngör
authors.initials: G
authors.lastname: Gündüz
authors.forename: Ufuk
authors.initials: U
authors.lastname: Gündüz
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D050091:Dendrimers / Q000138:chemical synthesis; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005227:Fatty Acids; D005260:Female; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D015255:Idarubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D008049:Lipase / Q000378:metabolism; D053758:Nanoparticles; D011108:Polymers; D012277:Ricinoleic Acids / Q000737:chemistry; D013629:Tamoxifen / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D050091:Dendrimers; D004337:Drug Carriers; D005227:Fatty Acids; D011108:Polymers; D012277:Ricinoleic Acids; D013629:Tamoxifen; D008049:Lipase; C030521:ricinoleic acid; D015255:Idarubicin